Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

10 Nov 2016 11:03

RNS Number : 8768O
GW Pharmaceuticals PLC
10 November 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Thomas Lynch

2.

Reason for the notification

a.

Position/status

Non-executive Director

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each ISIN: GB0030544687

 

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £7.90

Volume(s)

2,074

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

1 November 2016

f.

Place of the transaction

AIM, London

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFILLLLILIR
Date   Source Headline
25th Nov 20097:02 amRNSPatient Recruitment Completed for Sativex Study
25th Nov 20097:00 amRNSFinal Results
23rd Nov 20097:00 amRNSPositive Sativex Results in Cancer Pain
4th Nov 200912:15 pmRNSNotice of Results
30th Oct 20094:43 pmRNSBlocklisting Interim Review
30th Oct 20093:41 pmRNSTotal Voting Rights
17th Sep 20094:40 pmRNSSecond Price Monitoring Extn
17th Sep 20094:35 pmRNSPrice Monitoring Extension
17th Sep 20097:00 amRNSUpdate on cannabinoid pipeline
14th Sep 20097:00 amRNSResults from two clinical studies of Savitex(R)
10th Sep 20097:00 amRNSRodman and Renshaw Conference
18th Aug 20094:23 pmRNSHolding(s) in Company
18th Aug 20094:18 pmRNSTotal Voting Rights
6th Aug 20097:00 amRNSRe Agreement
28th Jul 200911:10 amRNSDirector/PDMR Shareholding
16th Jul 20097:00 amRNSManufacturing Licence Received for Sativex
26th Jun 20098:41 amRNSDirector/PDMR Shareholding
24th Jun 20099:19 amRNSDirector/PDMR Shareholding
16th Jun 20097:00 amRNSGW Expands Cannabinoid Research
15th Jun 20095:46 pmRNSDirector/PDMR Shareholding
2nd Jun 20097:00 amRNSHolding(s) in Company
1st Jun 20094:12 pmRNSNotification of Interests of Directors
21st May 20094:00 pmRNSDirector/PDMR Shareholding
20th May 20097:01 amRNSGW Files Sativex? Regulatory Submission
20th May 20097:00 amRNSInterim Results
20th Apr 20093:20 pmRNSNotice of Results
1st Apr 20097:00 amRNS?8m Milestone Payment from Almirall
31st Mar 20097:00 amRNSBlocklisting Interim Review
31st Mar 20097:00 amRNSTotal Voting Rights
30th Mar 200910:11 amRNSDirector/PDMR Shareholding
27th Mar 20094:51 pmRNSDirector/PDMR Shareholding
13th Mar 20099:34 amRNSNotification of Interests of Directors
11th Mar 20091:12 pmRNSPositive Outcome of Sativex Phase III MS Study
2nd Mar 20095:38 pmRNSDirector/PDMR Shareholding
24th Feb 20097:00 amRNSClinical Trial Update
16th Jan 20095:27 pmRNSDirector/PDMR Shareholding
14th Jan 20092:05 pmRNSResult of AGM
2nd Dec 20085:50 pmRNSDirector/PDMR Shareholding
18th Nov 20087:00 amRNSFinal Results
24th Oct 20084:47 pmRNSSecond Price Monitoring Extn
24th Oct 20084:37 pmRNSPrice Monitoring Extension
22nd Oct 200811:00 amRNSNotice of Results
10th Oct 20084:42 pmRNSPrice Monitoring Extension
1st Oct 20087:00 amRNSTrial Completes Recruitment
8th Sep 20087:00 amRNSResearch Update
18th Jul 20084:38 pmRNSDirector/PDMR Shareholding
24th Jun 20083:36 pmRNSBlocklisting Interim Review
24th Jun 20083:32 pmRNSBlocklisting Interim Review
24th Jun 20083:27 pmRNSBlocklisting Interim Review
24th Jun 20083:22 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.